secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivos Therapeutics, Inc. (VVOS)
CIK:        0001716166
Form:       8-K
Filed at:   2026-04-03T23:59:59+00:00
Accession:  0001493152-26-015132
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivos Therapeutics raises ~$2.39M in PIPE financing from V-Co 3; includes conversion of $1.4M bridge note
--------------------------------------------------------------------------------

- Sold 1,353,625 shares, pre-funded warrant for 429,957 shares, and Series A/B warrants for 1,783,582 each at $1.34 per unit.
- Cash proceeds of $850,000; $1,400,000 bridge note converted; gross proceeds $2,390,000.
- Series A/B warrants exercisable at $1.09 (2 and 5 year terms); pre-funded warrant exercisable at $0.0001.
- Company must file resale registration statement within 45 days and use best efforts for effectiveness within 90 days.
- Net proceeds to be used for general working capital purposes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716166/000149315226015132/0001493152-26-015132-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716166/000149315226015132/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-015132

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer